NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal

Imlifidase for preventing kidney transplant rejection in people with chronic kidney disease [ID1672]

Stakeholder list of consultees and commentators

Consultees	Commentators (no right to submit or
	appeal)
Company/sponsor	General commentators
Hansa Biopharma (imlifidase)	 All Wales Therapeutic and Toxicology Centre
Patient/carer groups	Allied Health Professionals Federation
Kidney Care UK	 Association of Renal Industries
Kidney Research UK	Board of Community Health Councils in
Muslim Council of Britain	Wales
National Kidney Federation	British National Formulary
 Network of Sikh Organisations 	Care Quality Commission
 Polycystic Kidney Disease Charity 	 Department of Health, Social Services
South Asian Health Foundation	and Public Safety for Northern Ireland
Specialised Healthcare Alliance	Healthcare Improvement Scotland
	Medicines and Healthcare Products
Professional groups	Regulatory Agency
Association of Anaesthetists	National Association of Primary Care
Association of Renal Technologists	 National Pharmacy Association
Association of Surgeons of Great	NHS Alliance
Britain and Ireland	NHS Confederation
British Association of Urological	Scottish Medicines Consortium
Nurses	Welsh Health Specialised Services
British Association of Urological	Committee
Surgeons	Welsh Kidney Patients Association
British Geriatrics Society	
British Renal Society	Possible comparators
British Transplantation SocietyESPIRIT	None
NHS Blood and Transplant	Relevant research groups
Renal Association	Cochrane Kidney and Transplant Group
Royal College of Anaesthetists	Genomics England
Royal College of General Practitioners	MRC Clinical Trials Unit
Royal College of Nursing	National Institute for Health Research
Royal College of Pathologists	
Royal College of Physicians	Associated Public Health Groups
Royal College of Surgeons	Public Health England
Royal Pharmaceutical Society	Public Health Wales
Royal Society of Medicine	
Society for DGH Nephrologists	

- TREND UK
- UK Clinical Pharmacy Association
- UK Renal Pharmacy Group

Others

- Department of Health and Social Care
- NHS England
- NHS Rotherham CCG
- NHS Surrey Downs CCG
- Welsh Government

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the company that manufactures the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and the Welsh Government and relevant NHS organisations in England.

The company that manufactures the technology is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Document (FAD).

All non-company consultees are invited to submit a statement¹, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Document (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; Healthcare Improvement Scotland; other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance, and the British National Formulary.

All non-company commentators are invited to nominate clinical specialists or patient experts.

¹Non-company consultees are invited to submit statements relevant to the group they are representing.